Review Shows Lasting Weight Loss for Very-Low-Energy Diets

This article originally appeared here.
Share this content:
Review Shows Lasting Weight Loss for Very-Low-Energy Diets
Review Shows Lasting Weight Loss for Very-Low-Energy Diets

THURSDAY, Jan. 21, 2016 (HealthDay News) -- Very-low-energy diets (VLEDs) seem to be beneficial for long-term weight loss, according to a review published online Jan. 18 in Obesity Reviews.

Noting that guidelines suggest that VLEDs should be used to treat obesity only when rapid weight loss is clinically indicated, Helen M. Parretti, M.D., from the University of Birmingham in the United Kingdom, and colleagues reviewed the literature to examine weight change associated with use of VLEDs. Data were included from randomized trials where the intervention included a VLED and the comparator was no intervention or an intervention that could be given in a general medical setting with overweight adults.

The researchers found that VLEDs combined with a behavioral program achieved −3.9 kg at one year compared with a behavioral program alone. At 24 months and 38 to 60 months, the differences were −1.4 kg and −1.3 kg, respectively. Premature discontinuation of treatment occurred in 19 and 20 percent of the VLED and comparator groups, respectively (relative risk, 0.96; 95 percent confidence interval, 0.56 to 1.66). There was one serious adverse event in the VLED group (hospitalization with cholecystitis) and none in the comparator group.

"Very-low-energy diets with behavioral programs achieve greater long-term weight loss than behavioral programs alone, appear tolerable, and lead to few adverse events, suggesting they could be more widely used than current guidelines suggest," the authors write.

Several authors disclosed financial ties to the weight loss industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »